



This is a repository copy of *P0885 The relationship between bone regulatory markers and bone turnover in renal osteodystrophy.*

White Rose Research Online URL for this paper:  
<https://eprints.whiterose.ac.uk/167088/>

Version: Accepted Version

---

**Proceedings Paper:**

Salam, S. [orcid.org/0000-0001-9236-3906](https://orcid.org/0000-0001-9236-3906), Gallagher, O., Gossiel, F. et al. (2 more authors) (2020) P0885 The relationship between bone regulatory markers and bone turnover in renal osteodystrophy. In: Nephrology Dialysis Transplantation. 57th ERA-EDTA Congress, 06-09 Jun 2020, Online conference. Oxford University Press (OUP) .

<https://doi.org/10.1093/ndt/gfaa142.p0885>

---

This is a pre-copied, author-produced version of an abstract accepted for publication in Nephrology Dialysis Transplantation. The version of record [Syazrah Salam, Orla Gallagher, Fatma Gossiel, Arif Khwaja, Richard Eastell, P0885 THE RELATIONSHIP BETWEEN BONE REGULATORY MARKERS AND BONE TURNOVER IN RENAL OSTEODYSTROPHY, Nephrology Dialysis Transplantation, Volume 35, Issue Supplement\_3, June 2020, gfaa142.P0885] is available online at:  
<https://doi.org/10.1093/ndt/gfaa142.P0885>

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

**Background and Aims:** Renal osteodystrophy is common in advanced chronic kidney disease (CKD) patients and is characterized by abnormal bone turnover and mineralization. Parathyroid hormone (PTH) increases bone turnover through osteoblast and osteoclast activation. Osteoprotegerin (OPG) is a decoy receptor of receptor activator of nuclear factor kappa- $\beta$  ligand and thus, inhibits osteoclast maturation. Meanwhile, sclerostin is an inhibitor of the Wnt signalling pathway and thus, inhibits osteoblast maturation. We aimed to assess the relationship between these bone regulatory markers and bone turnover as assessed by bone histomorphometry and bone turnover markers (BTMs).

**Method:** We recruited 43 CKD patients with  $eGFR < 30 \text{ ml/min/1.73m}^2$  or on dialysis. Fasting serum samples were analysed using Immunodiagnostic Systems automated assays (Boldon, UK) for intact PTH (iPTH) and BTMs such as bone alkaline phosphatase (bALP) and intact procollagen type 1 N-terminal propeptide (intact PINP) which are bone formation markers, and tartrate-resistant acid phosphatase 5b (TRAP5b) which is a bone resorption marker. OPG and sclerostin were analysed using manual ELISA by Biomedica (Vienna, Austria). Trans-iliac bone biopsy was performed after tetracycline labelling. Bone samples were analysed using quantitative histomorphometry. Normal bone turnover was defined as bone formation rate/bone surface (BFR/BS) of  $18 - 38 \mu\text{m}^3/\mu\text{m}^2/\text{year}$ . Spearman rank correlation was used to test the relationship between the variables.

**Results:** Median BFR/BS was  $32.12$  (IQR  $17.76 - 48.25$ )  $\mu\text{m}^3/\mu\text{m}^2/\text{year}$ . 26% of patients had low and 40% had high bone turnover. iPTH and OPG were positively correlated with BFR/BS ( $\rho = 0.42$ ,  $p < 0.01$  and  $\rho = 0.36$ ,  $p < 0.05$  respectively). Sclerostin was not correlated with BFR/BS. Furthermore, sclerostin did not correlate with bALP and intact PINP whereas OPG correlated with TRAP5b ( $\rho = 0.43$ ,  $p < 0.01$ ). iPTH correlated with bALP ( $\rho = 0.62$ ,  $p < 0.001$ ), intact PINP ( $\rho = 0.62$ ,  $p < 0.001$ ) and TRAP5b ( $\rho = 0.50$ ,  $p = 0.001$ ).

**Conclusion:** Circulating levels of iPTH and OPG were modestly associated with bone turnover but sclerostin was not. There are likely to be bone regulators other than iPTH, OPG and sclerostin which regulate bone turnover in renal osteodystrophy.

**Figure:** None